Why market adoption is challenging for biotech and medtech
Why promising clinical performance needs a clear pathway, evidence and value proposition to support adoption.
Updated
A promising healthcare innovation does not automatically become routine care. Adoption depends on the evidence, the people using it and the system that must fund and deliver it.
For biotech and medtech teams, the challenge is to make the value proposition concrete for each decision maker.
Start with the current pathway
Show how the innovation changes care compared with the relevant alternative. Define who is eligible, where it is used and which decisions change. An abstract claim of better performance is harder to assess than a clear pathway comparison.
Answer different stakeholder questions
- Clinicians: what changes for patients, and how reliable is the evidence?
- Hospital managers: what happens to capacity, workflow and costs?
- Payers: what additional health benefit is achieved, at what cost and budget impact?
These perspectives overlap, but their costs and time horizons may differ. State those differences explicitly.
Identify evidence gaps early
A model can explore the consequences of uncertain inputs and reveal which assumptions drive the value story. This helps prioritise evidence generation and prepare more focused conversations.
Modelling does not replace clinical evidence or regulatory assessment. It provides a structured way to connect available evidence with possible downstream outcomes.
Make implementation part of the case
Training, staffing, equipment and changes to care pathways affect feasibility. A cost-effective innovation can still face implementation barriers or require upfront investment.
Medip Analytics helps teams explore costs, health outcomes and resource use in relevant scenarios, so adoption discussions can focus on the evidence and the setting.